引用次数
引用: 53,530
H-指数: 104
I10-指数 : 405
出版物: 1,064
Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma
Michael J. Overman , Scott Kopetz , Sijin Wen , Paulo M. Hoff
Cancer 113 ( 8) 2038 -2045
88
2008
BRAF Mutations in Non-Metastatic Colorectal Cancer: Current Relevance and Future Implications
Van Morris , Wei Qiao , Scott Kopetz
Current Colorectal Cancer Reports 11 ( 6) 303 -310
2015
Addition of RAS Mutation Status May Strengthen the Predictive Model for Progression of Indeterminate Pulmonary Nodules
Yoshihiro Mise , Jean-Nicolas Vauthey , Scott Kopetz
Annals of Surgery 264 ( 2)
2016
Consensus molecular subtypes (CMS), markers of systemic inflammation (SI) and clinicopathological parameters in colorectal cancer (CRC).
Michael Lam , Allan Andresson Lima Pereira , Preeti Kanikarla Marie , Jennifer S Davis
Journal of Clinical Oncology 36 ( 15_suppl) e15600 -e15600
2018
Circulating tumor DNA profiling to identify patients with metastatic colorectal cancer with improved overall survival following Sym004 treatment.
Thomas Tuxen Poulsen , Michael Kragh , Cliff Ding , Mikkel W Pedersen
Journal of Clinical Oncology 36 ( 15_suppl) e15577 -e15577
1
2018
Refining the use of adjuvant oxaliplatin in clinical stage II or III rectal adenocarcinoma.
Ofer Margalit , Ronac Mamtani , Scott Kopetz , Yu-Xiao Yang
Journal of Clinical Oncology 36 ( 15_suppl) e15686 -e15686
2018
Actionable fusions in colorectal cancer using a cell-free circulating tumor DNA (ctDNA) assay.
Katherine Clifton , Victoria M. Raymond , A. Dasari , Kanwal Pratap Singh Raghav
Journal of Clinical Oncology 36 3507 -3507
3
2018
Distinct impacts of KRAS, NRAS and BRAF mutations on survival of patients with metastatic colorectal cancer.
Yucai Wang , Jonathan M. Loree , Cecilia Yu , Marcella Tschautscher
Journal of Clinical Oncology 36 3513 -3513
13
2018
Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR rechallenge.
Christine Megerdichian Parseghian , Jonathan M. Loree , Van Karlyle Morris , Allan Andresson Lima Pereira
Journal of Clinical Oncology 36 3511 -3511
9
2018
Circulating tumor DNA (ctDNA) as an early marker to monitor clinical benefit of regorafenib and TAS-102 in patients with metastatic colorectal cancer (mCRC).
Allan Andresson Lima Pereira , Michael Lam , Preeti Kanikarla Marie , Kanwal Pratap Singh Raghav
Journal of Clinical Oncology 36 3533 -3533
2
2018
Proteomic profiling of phosphatidylinositol 3-kinase (PI3K) altered metastatic colorectal cancer (mCRC) after protein kinase B (Akt) inhibition: Insulin like growth factor 1 receptor (IGF1R) mediates adaptive resistance.
Maliha Nusrat , Jisu Oh , Zhi-Qin Jiang , A. Dasari
Journal of Clinical Oncology 36 3549 -3549
1
2018
International harmonization of diagnostic criteria for HER2-amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method.
Satoshi Fujii , Anthony Martin Magliocco , Emanuele Valtorta , Jihun Kim
Journal of Clinical Oncology 36 3594 -3594
6
2018
The characteristics of ARID1A mutations in colorectal cancer.
Amir Mehrvarz Sarshekeh , Jonathan M. Loree , Ganiraju C. Manyam , Allan Andresson Lima Pereira
Journal of Clinical Oncology 36 3595 -3595
3
2018
Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer
Scott Kopetz , Van K Morris , Nila Parikh , Michael J Overman
BMC Cancer 14 ( 1) 660 -660
11
2014
Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma
Zhimin Tong , Devkumar Chatterjee , Defeng Deng , Omkara Veeranki
Oncotarget 8 ( 17) 28696 -28710
7
2017
FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma
Krittiya Korphaisarn , Van Karlyle Morris , Michael J. Overman , David R. Fogelman
Oncotarget 8 ( 24) 39268 -39279
51
2017
A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory
Natalia Paez Arango , Lauren Brusco , Kenna R. Mills Shaw , Ken Chen
Oncotarget 8 ( 26) 41806 -41814
9
2017
Abstract B17: Activating mutations of phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) gene confer sensitivity to PD-L1 checkpoint inhibition in metastatic adenocarcinoma patients
Maliha Nusrat , David Hong , Sarina A. Piha-Paul , Vivek Subbiah
Molecular Cancer Research 18
2020
Abstract PR10: PIK3CA mutations in plasma cell-free DNA predict survival and treatment outcomes in patients with advanced cancers
Ecaterina E. Ileana Dumbrava , Helen J. Huang , Ana Stuckett , Kiran Madwani
Molecular Cancer Research 18
2020
AMPKα1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation.
Ying-Nan Wang , Yun-Xin Lu , Jie Liu , Ying Jin
Oncogene 39 ( 3) 637 -650
15
2020